Therapeutic uses forbeto-blockers: on update
Keywords:
beta-adrenergic blockers, cardio vascular therapeuticsAbstract
Beta-blockers (fl-b) maintain an important role in the treament of cardiovascular diseases. They constitute a large group of agents, with reasonable complexity. They have vast uses and still new indications have evolved for new and old agents.
We started by reviewing the main pharmacological and pharmacokinetic characteristics of fl-b, with particular emphasis to clinicaly impor tant basic pharmacologic differences: potency, structure-activity relationships, membrane sta bilizing activity, selectivity, intrinsic simpathomimetic activity, alpha-adrenergic blocking ac tivity and the variable dose-therapeutic efficacy relationship, of these drugs.
The therapeutic indications for every condi tion were reviewed. Of particular importance are the beneficial effects of 3-b in survivers of myo cardial infarction, the efficacy of these agents in the treatment of hypertension and the promising uses of sotalol - a class III drug - in the treatment of cardiac arrhythmias. The experimental uses of fl-b in the treatment of dilated cardiomyopathy are also important.
Finnaly, the adverse effects of fl-b are discribed. Controversies surrounding their uses in patients with diabetes mellitus, peripheral vascular disease and dyslipidemia were discussed.
Downloads
References
Prichard B N C.Dal -adrenergic receptor blocking drugs in angina pectoris. Drugs 1974; 7: 55-84.
Frishman W H, Sonnenblick E. H. Beta-adrenergic blocking drugs. ln Hurst's the Heart, 8 th international edition, 1994: 1271- 1290.
Frishman WH. Beta-adrenergic blocker Withdrawal. Am J Cardiol 1987; 59: 26F-32F.
Opie LH, Sonnenblick EH, Frishman WH, Thadani U. Beta-blocking agents. ln Drugs for the Heart, 4mediton, 1995: 1-30
Parker J O, Porter A, Parker J D. Propanolol in angina pectoris: comparison of long acting and standard formulation propanolol. Circulation 1982; 65: 1351-1355.
Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. Cardiol Actual, 1994;33: 1160-1161.
Swanton RH. Beta-blocking agents. ln Cardiology pocket con sultant, 3'edition, Blackwell Scientific Publications 1994: 169- 172.
Crawford MH. Chronic ischemic heart disease. ln Current Diag nosis and Treatment in Cardiology, first edition, 1995: 27-39.
Singh BN, Deedwania P, Nademanee K, Ward A, Sorkin E. Sotalol: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1987; 34:311-349.
Opie LH: Drugs and the heart: Beta-blocking agents. Lancet 1980; 1: 693- 698.
Henry JA, Cassidy SL: Membrane stabilizing activity: a major cause of fatal poisoning. Lancet 1986; 1: 1414-1417.
Frishman WH: multifactorial actions of beta adrenergic blocking drugs in ischemic heart disease: Current concepts. Circulation 1983; 67(suppl): 111-118.
Landau AJ, Frishman WH, Alturk N, Adjei-Poku M, Fornasier Bongo M, Furia S. Improvement in exercise tolerance and imediate beta-adrenergic blockade with intranasal propanolol in patients with angina pectoris. Am J Cardiol 1993; 72: 995-998.
Bairey CN, Krantz DS, DeQuattro V, Berman DS, Rozanski A. Effect of beta-blockade on low heart rate-related ischemia during mental stress. J Am Coll Cardiol 1991; 17:1388-1395.
Packer M. Combined beta-adrenergic and calcium entry blockade in angina pectoris. N Eng! J Med 1989; 320 (11): 709-
Hills LD, Lange RA, Wells PJ, Winniford MD, Page LR. Treatment of Myocardial Infarction. ln Manual of Clinicai Problems in Cardiology, 5tl' edition, 1995: 146-148.
Pasternak RC, Braunwald E, Sobe! BE. Management of acute myocardial infarction. ln Braunwald Heart Disease, 4th edition, 1992:1223-1239 .
ISIS-1 (First lnternational Study of Infarct Survival) Collabora tive group. Randomized triai of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; 2:57-66.
MIAMI Triai Research Group: Metoprolol in Acute Myocardial Infarction (MIAMI): a randomized placebo-controlled in ternational triai. Eur Heart J 1985; 6:199-226.
TIMI-II-B study - Roberts R, Rogers WJ, Mueller HS, et ai, for the TIM! Investigators. Imediate versus deferred -blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIM!) 11-B study. Circulation 1991; 83: 422-437.
Augusti A, Arnan JM, Laporte R. Clinical trials versus clinical practice in the secondary prevention of myocardial infarction. Eur J Clin Pharm 1994; 46(2): 95-99.
Hlatky MA, Cotugno HE, Mark DB, O'Connor C, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987, 1988. Am J Cardiol 61:515-518.
Jansen RWMM, Gurwitz JH. Controversies surrounding the use of 8-blockers in older patients with cardiovascular disease. Drugs Aging 1994; 4 (3): 175-183.
Jaffe AS. Acute Myocardial Infarction. ln Current Diagnosis and Treatment in Cardiology, first edition, 1995: 50-86.
Bonow RO, Udelson JE. Left ventricular diastolic function as a cause of of congestive heart failure. Ann Intern Med 1992;117: 502-510.
Shah KS, Zahger D. Unstable angina. ln Current Diagnosis and Treatment in Cardiology, first edition, 1995: 40-49.
Hills LO, Lange RA, Wells PJ, Winniford MD, Page LR Exertional angina pectoris ln Manual of Clinicai Problems in Cardiology, 5th edition, 1995: 88-90.
Swanton RH. Management of unstable angina. ln Cardiology pocket consultant, 3rd edition, Blackwell Scientific Publications 1994: 186-189.
Hills LO, Lange RA, Wells PJ, Winniford MO, Page LR Silent Myocardial Ischemia , ln: Manual of Clinical Problems in Cardiology, 5th edition, 1995: 151-152.
Graettinger WF. Systemic hypertension. It Current Diagnosis and Treatment in Cardiology, first edition, 1995: 163-171.
Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, et al. A comparison of the efficacy and safety of a blocker, a caleium channel blocker, anda converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150:1707-1713.
Kaplan NM. Antypertensive drug therapy. It Braunwald Heart Disease, 4th edition, 1992: 858-874.
Komajda M, Grenevay B, Grosgogeat Y: Long term experience with Tertatolol in Hypertension. Am J Nephrol 1986; 6 (suppl 2): 106-112.
Agnes E, Vandermercken C, Prost J F, Safar M E. The Tertatolol International Multicenter Study (TIMS). Predicting factors of an efficient therapy. Am J Hypert 1989; 2: 296S-302S.
Guery O, Herpin D, Lecasble M, Piron J. Tertatolol in hypertension. Long term therapy in 2338 patients. Am J Hypert 1989;2: 289S-295S.
Verbeuren T J, Zonnekeyen L L, ProstJ F, et al. The beta-adre no receptor blocker tertatolol causes vasodilatation in the isolated perfused vasoconstricted kidney. J Pharmacol Exp Ther 1988;246: 628-634.
Bronze L, Martins D, Morgado F, Adragão P, Bonhorst D, Seabra-Gomes R. Orientação do doente com síndrome de Wolff-Parkinson-White-a propósito de um caso clínico. Cardiol Actual 1993; 24: 865-875.
Bonhorst D. Fármacos antiarrítmicos: ponto da situação. Rev Port Cardiol 1995; 14(5): 421-429.
ESVEM study - MasonJW for the Electrophysiologic Study Ver sus Electrocardiographic Monitoring. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 452-458.
Bonhorst D, Adragão P, Morgado F, Trabulo M, Mesquita A, Seabra-Gomes R. Importância do sotalol no tratamento de disritmias. Rev Port Cardiol 1994; 13 (supl.1):1-27.
Swanton RH. Hypertrophic obstrutive cardiomyopathy. lt Cardiology pocket consultant, 3rd edition, Blackwell Scientific Publications: 145-154.
Hills LO, Lange RA, Wells PJ, Winniford MD, Page RL. Hyper trophic Cardiomyopathy. lt Manual of Clinical problems in Cardiology, 5th edition, 1995: 191-193.
Shah P. Hypertrophic Cardiomyopathies. It Current Diagnosis and Treatment in Cardiology, first edition 1995: 172-178.
Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. lncreased B -receptor density and improved hemodynamic response to cathecolamine stimulation during long term metropolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989; 79: 483-490.
Waagstein F, Caidahl K, Wallentin !, Bergh C-H, Hjalmarson A. Long -term B-blockade in dilated cardiomyopathy: effects of short and long term metropolol teatment followed by with drawal and readministration of metropolol. Circulation 1989;80:551-563.
CIBIS investigators. A randomized triai of B-blockade in heart failure: the cardiac lnsufficiency Bisoprolol study (CIBIS) Circulation 1994; 90: 1765-1773.
Hills LO, Lange RA, Wells PJ, Winniford MO, Page RL. Dissecting Aortic Aneurysm. ln Manual of Clinical Problems in Cardiology, 5th edition, 1995: 498-499.
Wernly J A. Thoracic Aortic Dissection. Current Diagnosis and Treatment in Cardiology 1995: 456-468.
Hills LO, Lange RA, Wells PJ, Winniford MD, Page RL. Torsa de de Pointes and congenital long QT syndromes. lt Manual of Clinicai Problems in Cardiology, 5th edition, 1995: 33-34.
Correia MJ, Ribeiro C. As arritmias dos síndromes de QT longo. ln Arritmias Cardíacas: aspectos clínicos; editor J. Lopo Tuna, 1993: 311-325.
SI. Taylor SH, Silke B, Lee PS. Intravenous beta-blockade in coronary heart disease. N Engl J Med 1982; 306: 631- 635.
Martins C. Actualização das recomendações para uso clínico das provas de esforço. Fármacos e provas de esforço. ln 2ª Reunião sobre recomendações, competências e consensos em Cardiologia. Rev Port Cardiol 1994; 13 (suplemento II): 223-225.
De Blasi A, Lipartiti M. Les Interactions du tertatolol avec les recepteurs beta-adrenérgiques. Ann Med Interne 1987; 138:11-13.
Hiatt WR, Stoll S, Nies AS. Effect of B-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation 1985; 72(6): 1226-1231.
Farmer JA, Gotto AM. Risk Factors for coronary heart disease. ln: Braunwald Heart Disease, 4th edition, 1992:1139-1140.
Rutherford JD, Braunwald E. Beta-adrenoreceptor blocking agents. ln: Braunwald Heart Disease, 4th edition, 1992:1307- 1310
Ahumada GG. Identification of patients who do not require beta antagonists after myocardial infarction. Am J Med 1983; 76: 900-904.
Friedman LM. How do the various beta-blockers compare in type, frequency and severity of their adverse effects1 Circulation 1983; 67(11):189 - 190.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
